In Section A, contributors will receive diverse doses and schedules of oral ABBV-744 pill to determine safe dosing regimen. More participants is going to be enrolled on the determined monotherapy dosign program. In Phase B, participants will obtain oral ruxolitinib and ABBV-744 are going to be offered as "insert-on" therapy. https://paulu009grb2.like-blogs.com/profile